Loading...

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ
Healthcare
Biotechnology
$440.90
$-7.50(-1.67%)

Vertex Pharmaceuticals Incorporated VRTX Peers

See (VRTX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
VRTX$440.90-1.67%113.2B-115.12-$3.83N/A
REGN$509.72-0.75%54.1B12.96$39.32+0.35%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$309.70-0.84%40.4B-148.18-$2.09N/A
ARGX$542.15+0.79%33.1B33.04$16.41N/A
BNTX$106.53+2.04%25.6B-29.03-$3.67N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
RPRX$34.86-0.14%19.6B14.23$2.45+2.47%
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
SMMT$20.56+1.98%15.3B-60.47-$0.34N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

VRTX vs REGN Comparison

VRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 113.2B. In comparison, REGN has a market cap of 54.1B. Regarding current trading prices, VRTX is priced at $440.90, while REGN trades at $509.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of -115.12, whereas REGN's P/E ratio is 12.96. In terms of profitability, VRTX's ROE is -0.06%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRTX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRTX.

Stock Price Comparison

Loading...

Frequently Asked Questions

;